

# CHEMO PHARMA LABORATORIES LIMITED

• EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001  
 • TEL: 91-22-22078381, 22078382 • FAX: 91-22-22074294  
 • CIN No.: L99999MH1942FLC003556 • PAN No.: AAACC2056K  
 www.thechemopharmalaboratoriesltd.com  
 EMAIL: chemopharmalab@gmail.com

## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 31ST DECEMBER, 2014

(Rs in '000)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended 31st March, 2014
		31st December, 2014	30th September, 2014	31st December, 2013	31st December, 2014	31st December, 2013	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1	<b>Income from Operations</b>						
	(a) Net Sales/ Income from Operations (Net of excise)	-	-	-	-	-	-
	(b) Other Operating Income	325	1,134	227	2,563	2,014	4,388
	<b>Total Income from operations (net)</b>	<b>325</b>	<b>1,134</b>	<b>227</b>	<b>2,563</b>	<b>2,014</b>	<b>4,388</b>
2	<b>Expenses</b>						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchases of Stock-in-trade	-	-	-	-	-	-
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee benefits expenses	96	48	41	192	122	162
	(e) Depreciation and amortisation expense	16	9	11	27	34	46
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	(103)	269	26	208	183	255
	i) Professional Charges	45	63	49	107	346	841
	ii) Share Registry Expenses	20	26	-	64	-	68
	iii) Annual Listing Fees	125	-	-	125	-	-
	<b>Total Expenses</b>	<b>199</b>	<b>415</b>	<b>127</b>	<b>723</b>	<b>685</b>	<b>1,372</b>
3	<b>Profit / Loss from Operation before other Income, Finance cost and exceptional items (1-2)</b>	<b>127</b>	<b>719</b>	<b>100</b>	<b>1,840</b>	<b>1,329</b>	<b>3,016</b>
4	<b>Other Income</b>	-	-	-	-	-	-
5	<b>Profit / Loss from ordinary activities before Finance cost and exceptional items (3+4)</b>	<b>127</b>	<b>719</b>	<b>100</b>	<b>1,840</b>	<b>1,329</b>	<b>3,016</b>
6	<b>Finance Costs</b>	-	-	-	-	-	-
7	<b>Profit / Loss from ordinary activities after Finance cost but before exceptional items (5+6)</b>	<b>127</b>	<b>719</b>	<b>100</b>	<b>1,840</b>	<b>1,329</b>	<b>3,016</b>
8	<b>Exceptional Items</b>	-	-	-	-	-	-
9	<b>Net Profit/(Loss) from ordinary activities before tax (7+8)</b>	<b>127</b>	<b>719</b>	<b>100</b>	<b>1,840</b>	<b>1,329</b>	<b>3,016</b>
10	<b>Tax expenses</b>	-	-	-	-	-	605
11	<b>Net Profit/(Loss) from ordinary activities after tax (9+10)</b>	<b>127</b>	<b>719</b>	<b>100</b>	<b>1,840</b>	<b>1,329</b>	<b>2,411</b>
12	<b>Extra ordinary items (net of tax expenses Rs. )</b>	-	-	-	-	-	-
13	<b>Net Profit/ (Loss) for the period (11+12)</b>	<b>127</b>	<b>719</b>	<b>100</b>	<b>1,840</b>	<b>1,329</b>	<b>2,411</b>
14	<b>Share of Profit/ (Loss) of associate*</b>	-	-	-	-	-	-
15	<b>Minority interest *</b>	-	-	-	-	-	-
16	<b>Net Profit/ (Loss) after taxes, minority interest and share of profit / (loss) of associates 13+14+15*</b>	<b>127</b>	<b>719</b>	<b>100</b>	<b>1,840</b>	<b>1,329</b>	<b>2,411</b>
17	<b>Paid-up equity share Capital (face value of Rs. 10/- each)</b>	<b>15,000</b>	<b>15,000</b>	<b>15,000</b>	<b>15,000</b>	<b>15,000</b>	<b>15,000</b>
18	<b>Reserves excluding revaluation reserve as per balance sheet of previous accounting year</b>	<b>35,210</b>	<b>35,210</b>	<b>32,322</b>	<b>35,210</b>	<b>32,322</b>	<b>33,506</b>
19	<b>i) Earning per share (before extraordinary items) of Rs. 10/- each) (not annualised) :</b>						
	(a) Basic	0.08	0.48	0.07	1.23	0.89	1.61
	(b) Diluted						
19	<b>ii) Earning per share (after extraordinary items) of Rs. 10/- each) (not annualised) :</b>						
	(a) Basic	0.08	0.48	0.07	1.23	0.89	1.61
	(b) Diluted						



# CHEMO PHARMA LABORATORIES LIMITED

- EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001
- TEL: 91-22-22078381, 22078382 • FAX: 91-22-22074294
- CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
- www.thechemopharmalaboratoriesltd.com
- EMAIL: chemopharmalab@gmail.com

A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	- Number of shares	1,081,719	1,081,719	1,081,719	1,081,719	1,081,719	1,081,719
	- Percentage of shareholding	72.11	72.11	72.11	72.11	72.11	72.11
19	Promoters and Promoter Group shareholding**						
	a) Pledged/Encumbered						
	- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of company)	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non-Encumbered						
	- Number of shares	418,281	418,281	418,281	418,281	418,281	418,281
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100	100	100
	- Percentage of shares (as a % of the total share capital of company)	27.89	27.89	27.89	27.89	27.89	27.89

**Note :**

1. The above unaudited financial results have been taken on record by Audit Committee in their meeting on 20.01.2015 and also approved by the Board in their meeting held on 20.01.2015
2. Separate segment reporting is not applicable to the company.



Place : Mumbai  
Date : 20th January, 2015

By Order of the Board  
For Chemo - Pharma Laboratories Limited

*(Signature)*  
Director

**BATLIBOI & PUROHIT**  
**Chartered Accountants**


**REVIEW REPORT TO THE BOARD OF DIRECTORS OF**  
**CHEMO PHARMA LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited financial results of **Chemo Pharma Laboratories Ltd., ("the Company")** for the quarter ended 31<sup>st</sup> December, 2014 except for the disclosures regarding "Public Shareholding" and "Promoter and Promoter Group Shareholding" which have been traced from disclosures made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the independent Auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of audited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 Interim Financial Reporting, [notified pursuant to the Company's (Accounting Standards) Rules, 2006 as (amended)] and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place : Mumbai  
Dated : 20<sup>th</sup> January, 2015

**For BATLIBOI & PUROHIT**  
Chartered Accountants  
Firm Reg. No. 101048W

  
**Paresh Chokshi**  
Partner  
Membership No.33597